Every Form 4 that Labcorp Holdings Inc. (LH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LH filings page.
LABCORP HOLDINGS INC. (symbol: LH) is the issuer of record for a Form 4 filing submitted to the SEC. Oyegunwa Akinbolade reported acquisition or exercise transactions in this Form 4 filing.
LABCORP HOLDINGS INC. (LH) reported that executive vice president, chief information officer and chief technology officer Akinbolade Oyegunwa received a grant of 750 Restricted Stock Units on September 1, 2026. Each unit represents the contingent right to receive one share of common stock and vests in three equal annual installments beginning on September 1, 2027. After this award, Oyegunwa holds an aggregate of 2,940 Restricted Stock Units directly.
LABCORP HOLDINGS INC. (symbol: LH) is the issuer of record for a Form 4 filing submitted to the SEC. Meltzer Jonathan C reported acquisition or exercise transactions in this Form 4 filing.
LABCORP HOLDINGS INC. (LH) reported that executive vice president and chief operating officer Jonathan C. Meltzer received a grant of 900 Restricted Stock Units on September 1, 2026. Each unit represents the contingent right to receive one share of common stock and will vest in three equal annual installments beginning on September 1, 2027.
After this grant, Meltzer holds an aggregate of 3,594 Restricted Stock Units, representing potential future shares of Labcorp common stock if the vesting conditions are satisfied.
LABCORP HOLDINGS INC. (symbol: LH) is the issuer of record for a Form 4 filing submitted to the SEC. Vaughn Bryan T reported acquisition or exercise transactions in this Form 4 filing.
LABCORP HOLDINGS INC. (LH) reported that executive officer Bryan T. Vaughn, EVP and President, Diagnostics, received a grant of 1,500 Restricted Stock Units on September 1, 2026. Each unit represents the contingent right to receive one share of common stock and vests in three equal annual installments beginning on September 1, 2027. Following this award, Vaughn holds an aggregate of 5,204 Restricted Stock Units, all reported as directly owned.
LABCORP HOLDINGS INC. (symbol: LH) is the issuer of record for a Form 4 filing submitted to the SEC. Caveney Brian J reported acquisition or exercise transactions in this Form 4 filing.
LABCORP HOLDINGS INC. (LH) reported that executive officer Brian J. Caveney, EVP, President of BLS, CMO & CSO, received a grant of 3,000 Restricted Stock Units on September 1, 2026. Each unit represents a contingent right to receive one share of Labcorp common stock and vests in three equal annual installments beginning on September 1, 2027.
After this grant, Caveney holds a total of 7,170 Restricted Stock Units directly. No Rule 10b5-1 trading plan is reported in connection with this award.
LABCORP HOLDINGS INC. director Kerrii B. Anderson reported selling 3,000 shares of common stock on 2026-08-17 at $318.02 per share in an open-market or private transaction made pursuant to a Rule 10b5-1 trading plan. After this sale, she held 6,563 shares directly and 144 shares indirectly in each of two separate trusts.
LABCORP HOLDINGS INC. President & CEO Adam H. Schechter reported a sale of common stock. On 2026-08-11, he sold 4,669 shares of Labcorp common stock at a price of $320.37 per share in an open-market or private transaction. After this transaction, he directly holds 102,565 shares of common stock. The sale was executed pursuant to a pre-established trading plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.
Amy B. Summy, EVP and Chief Marketing Officer of Labcorp Holdings Inc., reported a sale of 924.0000 shares of Common Stock on 2026-08-04 at $306.7400 per share in a sale classified as an open-market or private transaction. After this sale, she directly owns 6955.5000 shares.
Labcorp Holdings Inc. senior vice president and chief accounting officer Peter J. Wilkinson exercised 1,338 non-qualified stock options at an exercise price of $209.25 per share, receiving 1,338 common shares. On the same date he sold 1,420 common shares in open-market transactions at prices of $309.22 and $309.2311 per share. The specific option grant, issued under Labcorp's Amended and Restated 2016 Omnibus Incentive Plan, is now fully exercised.
Labcorp Holdings Inc. EVP and Chief Legal Officer Kathryn W. Kyle reported several equity transactions involving company stock. On July 1, 2026, she exercised 256 Restricted Stock Units, receiving the same number of common shares, while 73 shares were withheld to cover tax obligations. On July 2, 2026, she made an open-market sale of 92 common shares at $286.19 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she directly holds about 3,904.4574 common shares, and the filing notes an aggregate holding of 2,008 Restricted Stock Units.
Labcorp Holdings executive Bryan T. Vaughn reported an option-style vesting and a small open-market sale of company stock. On July 1, 2026, 327 Restricted Stock Units converted into the same number of Labcorp common shares, while 93 shares were withheld to cover tax obligations.
On July 2, 2026, Vaughn sold 234 common shares in an open-market transaction at $286.19 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 6,745.5702 Labcorp shares and 3,704 Restricted Stock Units in total.
LABCORP HOLDINGS INC. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported an open-market sale of Common Stock. On June 8, 2026, she sold 762 shares at $263.89 per share in a transaction made under a pre-arranged Rule 10b5-1 trading plan. After this sale, she directly owns about 3,813.4574 shares of Labcorp common stock.
LABCORP HOLDINGS INC. President & CEO Adam H. Schechter sold 5,903 shares of Common Stock in an open-market transaction at a price of $254.50 per share on May 11, 2026. The sale was made pursuant to a pre-established Rule 10b5-1 trading plan.
Following this transaction, Schechter directly holds 107,234 shares of Labcorp Common Stock, indicating he retains a substantial equity position in the company while executing a planned share sale.
LABCORP HOLDINGS INC. President & CEO Adam H. Schechter received a grant of 58,470 shares of Common Stock on March 26, 2026, as a performance award tied to results for the three-year period ended December 31, 2025. To cover related tax obligations, 26,106 shares of Common Stock were withheld at $268.38 per share rather than sold in the open market. After these compensation and tax-withholding entries, Schechter directly holds 113,137 shares of Common Stock.
LABCORP HOLDINGS INC. executive Anita Z. Graham, EVP and CHRO, received 6,604 shares of common stock on March 26, 2026 as a performance-based equity award. The award relates to performance over the three-year period ended December 31, 2025 from a grant made on April 5, 2023.
To cover tax withholding obligations, 2,879 shares were automatically withheld at $268.38 per share, which is recorded as a disposition but is not an open-market sale. After these transactions, Graham directly holds 5,185 shares of Labcorp common stock.
LABCORP HOLDINGS INC. executive Mark S. Schroeder, EVP and President of Diagnostics & COO, reported equity compensation activity in the company’s common stock. On March 26, 2026, he acquired 9,304 shares pursuant to a performance award granted on February 7, 2023 and 2,968 shares pursuant to a performance award granted on May 5, 2023, both tied to performance for the three-year period ended December 31, 2025. To cover tax withholding obligations, 4,600 shares and 1,468 shares were withheld at a price of $268.38 per share. Following these grant and tax-withholding transactions, he directly held 12,677.1426 shares of common stock.
LABCORP HOLDINGS INC. executive Brian J. Caveney, EVP and President of Enterprise Diagnostics, CMO & CSO, reported stock-based compensation and related tax withholding. On March 26, 2026, he acquired 9,304 and 1,986 shares of common stock from performance awards tied to the three-year period ended December 31, 2025. To satisfy tax withholding obligations, 4,042 and 863 shares were withheld at $268.38 per share. After these transactions, he directly owned 36,491.9234 shares of Labcorp common stock.
Labcorp Holdings senior vice president and chief accounting officer Peter J. Wilkinson reported a mix of equity compensation and related share dispositions. On March 26, 2026, he acquired 2,388 shares of common stock at $0.00 per share pursuant to a performance award covering the three-year period ended December 31, 2025. That same day, 755 shares were withheld at $268.38 per share to satisfy tax withholding obligations, leaving 3,485.2194 shares directly owned. On March 27, 2026, he executed an open-market sale of 1,633 shares at an average price of $267.05 per share under a pre-arranged Rule 10b5-1 trading plan, resulting in direct ownership of 1,852.2194 shares.
LABCORP HOLDINGS INC. executive EVP, Diagnostics Bryan T. Vaughn received 1,584 shares of common stock on March 26, 2026 as a performance award tied to results over the three-year period ended December 31, 2025. To cover tax obligations, 451 shares were withheld at $268.38 per share, leaving him with 6,745.5702 directly owned shares after these transactions.
LABCORP HOLDINGS INC. executive Sandra D. van der Vaart, EVP, Corporate Affairs, received a grant of 6,382 shares of common stock on March 26, 2026. The award was earned under a performance plan covering the three-year period ended December 31, 2025.
To cover tax withholding obligations on this award, 2,722 shares were withheld at a price of $268.38 per share, rather than sold in the open market. After these transactions, she directly holds 6,238.9467 shares of Labcorp common stock.
LABCORP HOLDINGS INC. executive Amy B. Summy received 3,994 shares of common stock on March 26, 2026, as a performance award tied to the three-year period ended December 31, 2025. To cover tax obligations, 1,836 shares were withheld at $268.38 per share, leaving her with 7,879.5 shares held directly after these transactions.
Labcorp Holdings EVP, CIO & CTO Akinbolade Oyegunwa received 1,340 shares of common stock as a performance-based award. The award relates to company performance over the three-year period ending December 31, 2025. On the same date, 382 shares were withheld at $268.38 per share to satisfy tax withholding obligations, resulting in a net increase in holdings. After these transactions, Oyegunwa directly owns 5,064.253 shares of Labcorp common stock.
LABCORP HOLDINGS INC. executive vice president of operations Jonathan C. Meltzer reported a mix of equity compensation and routine share sales. On March 26, 2026, he acquired 2,388 shares of common stock at no cost through a performance award tied to results for the three-year period ended December 31, 2025. That same day, 711 shares were withheld to cover tax obligations. On March 27, 2026, he conducted an open-market sale of 839 shares at $267.05 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 3,620.3256 shares of Labcorp common stock.
LABCORP HOLDINGS INC. executive Kathryn W. Kyle, EVP and Chief Legal Officer, received a grant of 1,584 shares of common stock on March 26, 2026 pursuant to a performance award tied to a three-year period ending December 31, 2025. To cover tax withholding obligations, 451 shares were disposed of through stock withholding at $268.38 per share, leaving her with 4,575.4574 shares of common stock held directly after these transactions. These events reflect compensation-related share awards and associated tax withholding rather than open-market trading.
LABCORP HOLDINGS INC. executive Megan D. Bailey received an award of 1,184 shares of common stock on March 26, 2026, as part of a performance award granted on February 7, 2023 for a three-year period ending December 31, 2025. To cover tax withholding obligations, 481 shares were withheld at a price of $268.38 per share, leaving her with 4,851 shares of common stock held directly after these transactions. These movements reflect compensation-related equity awards and associated tax withholding rather than open-market trading.
LABCORP HOLDINGS INC. President & CEO Adam H. Schechter sold 8,705 shares of common stock in an open-market transaction on March 3, 2026 at an average price of $279.9595 per share. After this sale, he directly owned 80,773 shares of Labcorp common stock.
LABCORP HOLDINGS INC. executive Sandra D. van der Vaart, EVP of Corporate Affairs, reported an open-market sale of common stock. On February 27, 2026, she sold 547.5397 shares at an average price of $284.9100 per share. After this transaction, she directly owns 2,578.9467 shares of Labcorp common stock.
LABCORP HOLDINGS INC. executive Brian J. Caveney, EVP and President of Enterprise Diagnostics, Chief Medical Officer and Chief Scientific Officer, reported an open-market sale of common stock. On February 24, 2026, he sold 1,500 shares at an average price of $286.305 per share.
After this transaction, Caveney directly owns 30,106.9234 shares of Labcorp common stock. This filing reflects an insider reducing his direct shareholdings through a routine open-market sale.
LABCORP HOLDINGS INC. senior vice president and chief accounting officer Peter J. Wilkinson reported an open-market sale of common stock. On February 19, 2026, he sold 666 shares of Labcorp common stock at a price of $277.94 per share in a transaction coded as an open-market sale. After this sale, he directly owns 1,852.2194 shares of Labcorp common stock. The transaction was executed under a pre-established trading plan adopted in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.
Labcorp Holdings Inc. executive Amy B. Summy reported equity compensation activity involving Restricted Stock Units and common stock. On February 11, 2026, 230 Restricted Stock Units were exercised into 230 shares of Labcorp common stock at an exercise price of $0, increasing her directly held common shares to 5,804.5.
On the same date, 83 shares of common stock were automatically withheld at a price of $289.89 per share to cover tax withholding obligations, leaving her with 5,721.5 directly owned shares. The RSUs were part of a grant vesting in three equal annual installments beginning on February 11, 2026, and she held 1,304 Restricted Stock Units after these transactions.
Wilkinson Peter J reported multiple insider transaction types in a Form 4 filing for LH. The filing lists transactions totaling 1,598 shares at a weighted average price of $289.89 per share. Following the reported transactions, holdings were 2,128 shares.
Labcorp Holdings Inc. Chief Financial Officer and EVP Julia Aijun Wang exercised previously granted restricted stock units, receiving 860 shares of common stock on February 11, 2026. Each unit converts into one share of common stock.
To cover tax withholding obligations, 245 shares of common stock were withheld at a price of $289.89 per share. After these transactions, Wang directly holds 1,817.239 shares of common stock and 4,964 restricted stock units, which continue to vest in three equal annual installments beginning February 11, 2026.
Vaughn Bryan T reported multiple insider transaction types in a Form 4 filing for LH. The filing lists transactions totaling 739 shares at a weighted average price of $289.89 per share. Following the reported transactions, holdings were 4,031 shares.
Labcorp Holdings Inc. executive Sandra D. van der Vaart reported equity award activity and related tax withholding. On February 11, 2026, she exercised 376 Restricted Stock Units, converting them into 376 shares of common stock at an exercise price of $0 per share.
After this conversion, her directly held common stock position was 3,225.4864 shares before tax withholding. To cover tax obligations, 99 shares of common stock were withheld at a price of $289.89 per share, leaving 3,126.4864 shares of common stock held directly. Following the transaction, she also held 1,141 Restricted Stock Units, each representing the right to receive one common share as they vest in three equal annual installments beginning on February 11, 2026.
Labcorp Holdings Inc. executive Mark S. Schroeder, EVP, President Diagnostics & COO, reported equity award activity involving restricted stock units and common shares. On February 11, 2026, he converted 806 Restricted Stock Units into an equal number of common shares at an exercise price of $0 per share.
To satisfy tax withholding obligations, 259 common shares were withheld at a price of $289.89 per share. Following these transactions, Schroeder directly holds 6,473.1426 shares of Labcorp common stock and 2,358 Restricted Stock Units, which each represent the right to receive one share of common stock.
Labcorp Holdings Inc. President and CEO Adam H. Schechter reported several equity transactions dated February 11, 2026. He sold 5,273 shares of common stock in an open-market transaction at $284.38 per share under a Rule 10b5-1 trading plan.
On the same day, he acquired 3,656 shares of common stock through the exercise and conversion of Restricted Stock Units, and 1,521 shares were withheld to cover tax obligations. Following these transactions, he directly held 89,478 common shares and 22,214 Restricted Stock Units, each RSU representing the right to receive one share of common stock.
Labcorp Holdings Inc. executive Akinbolade Oyegunwa exercised restricted stock units and had shares withheld for taxes. On February 11, 2026, 230 restricted stock units converted into 230 shares of common stock. Of these, 68 shares were withheld to cover tax obligations at $289.89 per share.
Following these transactions, Oyegunwa directly held 4,106.253 shares of common stock and 2,190 restricted stock units. The vested units came from a grant scheduled to vest in three equal annual installments beginning on February 11, 2026.
Labcorp Holdings Inc. executive Jonathan C. Meltzer, EVP, Operations, reported several equity transactions in Labcorp common stock. On February 11, 2026, he acquired 243 shares of common stock through the vesting and conversion of 243 Restricted Stock Units, each RSU representing one share of common stock.
To cover taxes related to this vesting, 70 shares were withheld at a price of $289.89 per share. On February 12, 2026, he executed an open‑market sale of 87 shares at an average price of $290.42 per share under a pre‑arranged Rule 10b5‑1 trading plan. After these transactions, he directly held 2,782.3256 shares of common stock and 2,694 Restricted Stock Units.
Labcorp Holdings Inc. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported equity award activity on February 11, 2026. She acquired 216 shares of common stock at $0 through the vesting and conversion of Restricted Stock Units, each representing one share of common stock. To cover tax withholding obligations, 62 shares of common stock were withheld at a price of $289.89 per share. After these transactions, she directly owned 3,442.4574 shares of common stock and 2,264 Restricted Stock Units in total.
Labcorp Holdings Inc. executive Anita Z. Graham reported routine equity award activity. On February 11, 2026, 356 Restricted Stock Units converted into 356 shares of common stock at an exercise price of $0. To cover tax withholding, 109 shares of common stock were withheld at $289.89 per share. After these transactions, Graham directly owned 1,460 shares of common stock and 2,401 Restricted Stock Units, which continue to vest in three equal annual installments starting February 11, 2026.
Labcorp Holdings Inc. executive Brian J. Caveney, EVP and President of Enterprise Diagnostics, CMO & CSO, reported equity award activity in company stock. On February 11, 2026, he exercised 740 Restricted Stock Units, converting them into 740 shares of Common Stock at an exercise price of $0 per share.
To cover tax withholding obligations related to this vesting, 211 shares of Common Stock were withheld at a price of $289.89 per share, coded as a disposition for tax payment rather than an open-market sale. After these transactions, he directly held 31,606.9234 shares of Common Stock and 4,170 Restricted Stock Units, which vest in three equal annual installments beginning on February 11, 2026.
Labcorp Holdings Inc. executive Megan D. Bailey reported equity compensation activity involving restricted stock units and common shares. On February 11, 2026, 403 restricted stock units were converted into 403 shares of common stock, increasing her directly held common shares to 4,286. To cover tax withholding obligations, 138 common shares were withheld at a price of $289.89 per share, leaving her with 4,148 directly owned common shares. Following these transactions, she also directly holds 2,827 restricted stock units that vest in three equal annual installments beginning on February 11, 2026.
Labcorp Holdings Inc. director Paul Rothman reported acquiring shares through the vesting of equity awards. On February 11, 2026, he exercised 897 Restricted Stock Units, which converted into 897 shares of Labcorp common stock at an exercise price of $0 per share.
Following this transaction, Rothman directly owned 2,571 shares of Labcorp common stock and held 773 Restricted Stock Units, which represent rights to receive the same number of common shares. The filing reflects routine equity compensation vesting rather than an open‑market purchase or sale.
Labcorp Holdings Inc. director Kathryn E. Wengel increased her direct common stock holdings through equity compensation. On February 11, 2026, 897 Restricted Stock Units were exercised for 897 shares of Labcorp common stock at an exercise price of $0 per share.
After this conversion, Wengel directly owned 4,133 shares of Labcorp common stock. She also held 773 Restricted Stock Units as of that date, with each unit representing the contingent right to receive one share of Labcorp common stock upon vesting.
Labcorp Holdings Inc. director Richelle P. Parham acquired 897 shares of common stock on February 11, 2026 through the exercise and conversion of restricted stock units (RSUs) at $0 per share. This reflects equity compensation vesting rather than an open‑market purchase.
Following the transaction, Parham directly owns 3,366 shares of Labcorp common stock and holds 773 restricted stock units, each representing the contingent right to receive one share of common stock when they vest.
Labcorp Holdings Inc. director Peter M. Neupert reported the vesting and exercise of equity awards. On February 11, 2026, he exercised 897 Restricted Stock Units, converting them into 897 shares of Common Stock at an exercise price of $0 per share. Following this derivative conversion, he directly owned 13,784 shares of Common Stock and 773 Restricted Stock Units, each RSU representing the right to receive one Labcorp common share.
Labcorp Holdings director Garheng Kong reported acquiring shares through the vesting and conversion of restricted stock units. On February 11, 2026, 897 Restricted Stock Units converted into 897 shares of common stock at an exercise price of $0 per share.
Each Restricted Stock Unit represents the right to receive one Labcorp common share. After this transaction, Kong directly holds 13,739 shares of common stock and 773 Restricted Stock Units, which reflects the remaining aggregate RSU balance.
Labcorp Holdings Inc. director Kirsten Marie Kliphouse reported acquiring 897 shares of common stock through the vesting and conversion of restricted stock units. The RSUs fully vested on February 11, 2026, and after the transaction she directly holds 3,160 Labcorp common shares and 773 restricted stock units.
Labcorp Holdings Inc. director Jeffrey A. Davis acquired common shares through equity compensation. On February 11, 2026, 897 Restricted Stock Units were exercised/converted at $0 into 897 shares of Labcorp common stock. After this transaction, Davis directly held 5,460 common shares and 773 Restricted Stock Units.
Labcorp Holdings Inc. director Kerrii B. Anderson reported the vesting and exercise of 897 Restricted Stock Units on February 11, 2026, converting them into an equal number of Labcorp common shares at $0 per share. Following this derivative conversion, she directly holds 9,563 common shares and 773 remaining Restricted Stock Units, plus indirect holdings of 144 common shares in each of two separate trusts.
Labcorp Holdings Inc. reported that its President, CEO and director Adam H. Schechter received new equity awards on February 10, 2026. He was granted 31,700 non-qualified stock options with a $284.50 exercise price, vesting in three equal annual installments and expiring in 2036.
He also received 10,440 Restricted Stock Units (RSUs), each representing one share of Labcorp common stock, which vest in three equal annual installments beginning on February 10, 2027. Following this grant, he holds an aggregate of 25,870 RSUs.